Neurodegenerative Diseases

194 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Nervous System Diseases

Narrower: Alzheimer Disease 94, Bulbo-Spinal Atrophy, X-Linked 2, Charcot-Marie-Tooth Disease 1, Corticobasal Degeneration 1, Dysautonomia, Familial 1, Hereditary Sensory and Autonomic Neuropathies 15, Huntington Disease 7, Lewy Body Disease 3, Multiple System Atrophy 4, Muscular Atrophy, Spinal 9, Parkinson Disease 56, Spinal Muscular Atrophies of Childhood 4, Spinocerebellar Degenerations 3

Treatments and conditions

Neurodegenerative Diseases
Treatment and conditionWhere it standsTrials
[F-18]Flornaptitril for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
1 mg QD to 15 mg QD PF-06649751 for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
120 milligrams of ENERGI-F705 Tablets for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
15 mg QD PF-06649751 for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
3 mg QD to 15 mg QD PF-06649751 for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
40 Hz sound stimulation for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
40 Hz Synchronous Audio-Visual Stimulation for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
60 milligrams of ENERGI-F705 Tablets for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
7 mg QD to 15 mg QD PF-06649751 for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
AADvac1 for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Aav-gad for parkinson diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AB-1001 Gene Therapy for huntington diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AB-1005 for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Activa PC+S Neurostimulator for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
AD04 for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
AD5-NCOV for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Adaptive (Closed Loop) DBS + Intermittent Open Loop DBS + Open Loop DBS for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Adaptive (Closed Loop) DBS + Open Loop DBS for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Adaptive DBS for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)5
Adaptive DBS (Activa PC+S Neurostimulator) + Continuous DBS (Activa PC+S Neurostimulator) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
adaptive DBS (aDBS) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
adaptive DBS delivered through AlphaDBS IPG System for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
adaptive deep brain stimulation + conventional deep brain stimulation for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
aDBS-Extended (Medtronic Percept™) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Administer Leqemi 10 mg/kg, every two weeks. for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Aducanumab for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)4
Ambroxol for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ambroxol hydrochloride for lewy body diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Apitegromab for spinal muscular atrophies of childhoodPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
apomorphine infusion for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ATTN201 Focused Ultrasound to the CMN for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Atuzaginstat for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Audiovisual stimulation VR system for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
autologous dopaminergic cell implantation for parkinson diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Autologous midbrain dopamine neurons for parkinson diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BBB opening for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
BIIB122 for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BIIB122 225 mg for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Blood Brain Barrier (BBB) Disruption for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)2
Buntanetap for alzheimer diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Buntanetap tartrate for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
CapeOX + bevacizumab + PD-1 Inhibitors + SBRT for spinocerebellar degenerationsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Capivasertib for hereditary sensory and autonomic neuropathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + ELRAGLUSIB for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + ELRAGLUSIB + Paclitaxel for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cervical Lymphatic Microsurgery for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Cervical Lymphaticovenous and Lymph Node-to-Vein Anastomosis for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Closed-loop stimulation + GPi alone + STN + GPi + STN alone for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Combined metabolic activators for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Communication Bridge™ for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CUE1 for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CUE1 non-invasive device for corticobasal degenerationTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CUE1 non-invasive device for multiple system atrophyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CUE1 non-invasive device for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CVN424 150 mg for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
CVN424 75 mg for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
DC-LVA treatment plus usual care for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Deep Brain Stimulation, DBS for alzheimer diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Deep cervical lymph node to venous bypass (DCLNV-BP) for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Deep cervical lymphatic-venous anastomosis for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Deep cervical lymphatic-venous anastomosis, LVA for alzheimer diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Deep Cervical Lymphaticovenous Anastomosis(DLVA) for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Deep Cervical Lymphaticovenous Anastomosis(DLVA) for lewy body diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Deep Cervical Lymphaticovenous Anastomosis(DLVA) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Deep Cervical lymphatlc-Venous Anastomosis Surgery for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Deep cervical lymphovenous anastomosis (LVA) for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Deep Cervical Lymphovenous Anastomosis + Routine Treatment for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Device-only fitting for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Dexmedetomidine hydrochloride for dysautonomia, familialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Diet + Exercise + Meditation for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Donanemab for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)10
Donanemab for lewy body diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Donanemab + 2-Pyrazinecarboxamide, N-[3-[(4aR,7aS)-2-amino-6-(5-fluoro-2-pyrimidinyl)-4a,5,6,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a(4H)-yl]-4-fluorophenyl]-5-methoxy- for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Donanemab + Dexamethasone for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Donanemab + Nivegacetor for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Doxorubicin hydrochloride + ELRAGLUSIB for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
DSP-1083 implantation for parkinson diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elraglusib for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELRAGLUSIB + Gemcitabine Hydrochloride for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELRAGLUSIB + NAB-PACLITAXEL + Gemcitabine Hydrochloride for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Emestedastat for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Etanercept for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ExAblate 4000 Type 2.1 for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Exablate Model 4000 Type 2 + ADUCANUMAB + LECANEMAB for alzheimer diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Exenatide for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)3
Facilitate tDCS + CR for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Fasudil for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
FLORTAUCIPIR F-18 for neurodegenerative diseasesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
FLUOROETHOXYBENZOVESAMICOL F-18 for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Focused Transcranial Ultrasound for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Focused Transcranial Ultrasound for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for hereditary sensory and autonomic neuropathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + Tersolisib for hereditary sensory and autonomic neuropathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Gam-COVID-Vac for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
GammaSense Stimulation device for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Gantenerumab for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)3
GC101 for muscular atrophy, spinalPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GENUS device (Active Settings) for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
GV-971 for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
GV-971 + MEMANTINE for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
High doses of Thiamine y Biotin for huntington diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
High-Intensity Aerobic Exercise (AE) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
human Mesenchymal Stem Cells for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
intermittent theta burst stimulation (iTBS) for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
intermittent theta burst stimulation (iTBS) + METHYLPHENIDATE HYDROCHLORIDE for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
intra-striatal rAAV5-miHTT for huntington diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
IPILIMUMAB + SINTILIMAB + Cetuximab + DABRAFENIB for spinocerebellar degenerationsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan + ELRAGLUSIB for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
JNJ-64042056 for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ketamine for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lecanemab for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)6
LECANEMAB + Etalanetug for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Lifus for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Lixisenatide for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lomustine + ELRAGLUSIB for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
low intensity focused ultrasound (LIFU) for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
LY-2599666 for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
LY3002813 for alzheimer diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
LY3002813-IV for alzheimer diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
LY3002813-SC for alzheimer diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
LY3884961 + Sirolimus + Methylprednisolone for parkinson diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents + Neuronavigation-guided single-element focused ultrasound transducer + Positron Emission Tomography (PET) + FLORBETAPIR F-18 + PERFLUTREN for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Matching Placebo (E2814) + LECANEMAB for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Memantine for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Metformin for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mevidalen for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
MK-1167 for alzheimer diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
Moderate doses of Thiamine y Biotin for huntington diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Modified deep cervical Lymphatic-Venous Anastomosis for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Modified deep cervical Lymphatic-Venous Anastomosis for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
MR guided low intensity focused ultrasound for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
NanoLithium® NP03 for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nicotinamide Riboside (NR) for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Nivegacetor for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
NMS-01 for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
OAV101 for bulbo-spinal atrophy, x-linkedPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Obicetrapib 10 mg for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Onasemnogene abeparvovec for bulbo-spinal atrophy, x-linkedPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Onasemnogene abeparvovec for muscular atrophy, spinalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Onasemnogene abeparvovec for spinal muscular atrophies of childhoodPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
PBT-434 for multiple system atrophyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
PEMBROLIZUMAB + Porustobart for spinocerebellar degenerationsTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Percept™ PC and Percept RC with Adaptive DBS (aDBS™) for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
PF-06649751 high dose (15 mg QD) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
PF-06649751 low dose (1 mg QD) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
PF-06649751 middle dose 1 (3 mg QD) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
PF-06649751 middle dose 2 (7 mg QD) for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo + ADUCANUMAB for alzheimer diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)4
Placebo + Donanemab for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo + SRP-1005 for huntington diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo + TAVAPADON + TRIMETHOBENZAMIDE HYDROCHLORIDE for parkinson diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Prasinezumab for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
Psilocybin for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Psilocybin + PIMAVANSERIN for parkinson diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Receive tDCS+CR for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Recombinant varicella zoster virus glycoprotein e antigen for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
REPAIR Sleep for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Risdiplam for muscular atrophy, spinalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)6
ROC-101 for hereditary sensory and autonomic neuropathiesPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Semagludtide for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Service-only Fitting for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Simufilam for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)6
SKG0201 Injection for spinal muscular atrophies of childhoodPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sodium oligo-mannurarate 600mg for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Sodium oligo-mannurarate 900mg for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Sodium Oligomannate Capsules for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Solanezumab for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)7
Spinal Cord Stimulator (Octopolar Medtronic Vectris Leads) for spinal muscular atrophies of childhoodTrial registered, as of 19 Nov 2026 (not yet checked by a person)2
Supermicrosurgical Lymphaticovenular Anastomosis (LVA) for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
tACS combined with 40 Hz sound stimulation for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for hereditary sensory and autonomic neuropathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tavapadon for parkinson diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)7
Tersolisib for hereditary sensory and autonomic neuropathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
TEV-56286 for multiple system atrophyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
The LFP Beta aDBS System for parkinson diseaseTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Tominersen for huntington diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
Transcranial alternating current stimulation for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
transcranial magnetic resonance guided focused ultrasound BBB disruption for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
tributyrin for alzheimer diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Troculeucel for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Trontinemab for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Valacyclovir for alzheimer diseasePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Valiltramiprosate for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
VCA-894A for charcot-marie-tooth diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Votoplam (blinded) for huntington diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Wujia Yizhi granules for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Xanomeline Enteric Capsule + Xanomeline/Trospium Chloride Capsule for alzheimer diseasePhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
YA-101 for multiple system atrophyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.